Latest FDA Approvals Top AJPB Week in Review

Top news of the week from The American Journal of Pharmacy Benefits.

5. Use of Asthma, ADHD Drugs on the Rise in Children

Prescription medication use for attention-deficit/hyperactivity disorder (ADHD), asthma, and contraception have all increased in children and teens. Read more.

4. Anti-PD-1 Agents Reach Significant Amount of Patients Following FDA Approval

Following their approval, anti—PD-1 agents reach a significant proportion of patients within a few months, according to new study findings. Read more.

3. First Non-Opioid Treatment for Opioid Withdrawal in Adults Gains FDA Approval

The FDA approved lofexidine hydrochloride (Lucemyra) for the mitigation of opioid withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults, aged 18 and older. Read more.

2. President Trump Calls for Competition to Lower Drug Costs

President Trump today called for "tougher negotiation, more competition, and much lower prices at the pharmacy counter," in a statement on lowering drug prices. Read more.

1. FDA Approves Multiple Sclerosis Therapy for Use in Pediatric Patients

Officials with the FDA have approved fingolimod (Gilenya, Novartis) for the treatment of relapsing multiple sclerosis (MS) in pediatric patients aged 10 years and older. Read more.